hackint0sh/New-Dataset huggingface dataset:
These models would support clinicians in personalizing surgical and adjuvant treatment choice among the options considered by the international guidelines. conditions: Endometrial Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: As far as the sample size concerns, the number of images required for the analysis are a figure of at least 100 positive cases (15). We considered as positive patients with a favorable prognostic profile according to PORTEC-4a and also low and intermediate risk class according to ESGO/ESTRO/ESP 2020 recommendations.Therefore, we estimate to enroll at least 1000 patients in order to reach the 100 positive cases. primaryPurpose: DIAGNOSTIC masking: NONE count: 1000 type: ESTIMATED name: trascriptomic profiling measure: Predictive value of the model measure: Validity of the model sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Agostino Gemelli IRCSS status: RECRUITING city: Rome state: Lazio zip: 00118 country: Italy name: francesco fanfani role: CONTACT phone: 0630151 email: francesco.fanfani@policlinicogemelli.it lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06279819 id: 2024-008 briefTitle: Effectiveness of Gut Microbiota-targeted Dietary Intervention Among HIV-infected Patients overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Fudan University class: OTHER briefSummary: The goal of this clinical trial is to conduct a dietary intervention targeting HIV-specific gut microbiota alterations for primary ASCVD prevention and evaluate its effectiveness in preventing borderline ASCVD risk among HIV-infected patients. The main questions it aims to answer are:
Participants in the intervention group will receive the gut microbiota-targeted dietary intervention thrice weekly for 3 months, accompanied by bi-weekly health education videos for the same duration. Meanwhile, the control group will continue routine follow-up and health education practices. The intervention will span three months, followed by a three-month follow-up period. Data collection will occur at baseline, 3 months, and 6 months. conditions: Hiv conditions: Cardiovascular Diseases conditions: Diet, Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 106 type: ESTIMATED name: gut microbiota-targeted dietary intervention measure: ASCVD risk estimated by the PCE measure: The composition of gut microbiota measure: fasting blood lipids measure: blood pressure measure: BMI measure: ASCVD symptoms sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University city: Shanghai state: Shanghai zip: 200032 country: China name: Junwen Yu role: CONTACT phone: 13320178333 email: 13320178333@163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06279793 id: MODIFYCSX briefTitle: Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients. acronym: MODIFYCSX overallStatus: RECRUITING date: 2024-02-15 date: 2024-12-01 date: 2025-12-01 date: 2024-02-28 date: 2024-02-28 name: GCP-Service International West GmbH class: INDUSTRY name: Charite University, Berlin, Germany name: Wuerzburg University Hospital briefSummary: The proposing study is a randomized, double-blind, controlled trial of about 120 patients in 10 centers in Germany. This trial will be started in Germany and recruited mainly at powerful German heart centers only.
nctId: NCT06279767 id: 2022-SR-557 briefTitle: Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma overallStatus: RECRUITING date: 2022-07-01 date: 2025-07-01 date: 2025-07-31 date: 2024-02-28 date: 2024-02-28 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: Glioblastoma, the most prevalent malignant tumor in the central nervous system, is characterized by high invasiveness and a propensity to recur, contributing to a relatively elevated mortality rate. Patients diagnosed with high-grade glioblastomas typically experience a median survival period of less than 14 months. Presently, the standard treatment for glioblastoma involves surgical resection combined with postoperative radiotherapy and chemotherapy, with postoperative chemotherapy playing a pivotal role in enhancing patient prognosis. Temozolomide (TMZ), a cutting-edge oral alkylating agent known for its advantageous properties, including easy traversal of the blood-brain barrier, induces DNA alkylation in tumor cells, fostering apoptosis. Currently, it serves as a frontline medication for postoperative chemotherapy in glioblastoma. However, clinical resistance to TMZ chemotherapy significantly hampers its efficacy in later stages. We have recently discovered and validated that 5-aminoimidazole-4-carboxamide (AICA), derived from TMZ, can transform into 5-aminoimidazole-4-carboxamide ribonucleotide-5-phosphate (AICAR) in GBM cells. Hypoxanthine phosphoribosyltransferase 1 (HPRT1) has been identified as the catalyst for the AICA reaction, generating AICAR. AICAR acts as an endogenous activator of AMP-activated protein kinase (AMPK), fostering chemoresistance in glioblastoma through the activation of the AMPK signaling pathway. 6-mercaptopurine (6-MP) competes effectively to inhibit HPRT1 activity, thereby impeding TMZ-induced AMPK activation and significantly heightening glioblastoma cell sensitivity to TMZ. In this project, we propose an innovative strategy involving the combination of 6-MP with TMZ for the treatment of glioblastoma. conditions: Glioblastoma conditions: Cancer conditions: Temozolomide studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 27 type: ESTIMATED name: 6-mercaptopurine measure: PFS measure: OS measure: Safety evaluation sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Neurosurgery of The First Affiliated Hospital of Nanjing Medical University status: RECRUITING city: Nanjing state: Jiangsu zip: 210029 country: China name: Yongping You, PhD role: CONTACT phone: 13770694258 email: YYPL3@sohu.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06279754 id: ZLXGBXKYXM-031-01 briefTitle: Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy overallStatus: NOT_YET_RECRUITING date: 2024-02-18 date: 2024-06-18 date: 2025-12-18 date: 2024-02-28 date: 2024-02-28 name: The First Affiliated Hospital of Xinxiang Medical College class: OTHER briefSummary: This study is a prospective, single arm, single center open clinical study aimed at evaluating the efficacy and safety of recombinant human endostatin and envafolimab combined with synchronal radiochemotherapy in patients with locally advanced squamous non-small cell lung cancer who cannot undergo surgery in stage III. conditions: Locally Advanced Squamous Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Recombinant Human Endostatin Injection measure: objective response rate measure: Overall survival measure: Progression-free survival sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279741 id: EVENEW id: 2022-500293-34 type: EUDRACT_NUMBER id: U1111-1291-0283 type: OTHER domain: Universal Trial Number briefTitle: Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants acronym: EVENEW overallStatus: RECRUITING date: 2023-12-28 date: 2027-01-31 date: 2029-12-31 date: 2024-02-28 date: 2024-02-28 name: EXO Biologics S.A. class: INDUSTRY briefSummary: The phase 1/2 trial aims to evaluate the safety and efficacy of EXOB-001 consisting of extracellular vesicles derived from umbilical cord mesenchymal stromal cells in the prevention of bronchopulmonary dysplasia (BPD) in extremely premature neonates. The study population includes babies born between 23 and 28 (27 + 6 days) weeks of gestational age and body weight between 500g and 1,500 g. Thirty-six subjects will receive one or three administrations of the three doses of EXOB-001 via the endotracheal route in phase 1. In phase 2, two dosages based on the results of phase 1 will be selected and a total of 203 subjects will be randomised to receive either EXOB-001 or placebo (saline solution).
nctId: NCT06279728 id: DS1062-0003-EAP-MA briefTitle: Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients overallStatus: AVAILABLE date: 2024-02-28 date: 2024-04-08 name: Daiichi Sankyo class: INDUSTRY name: AstraZeneca briefSummary: The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to Dato-DXd for eligible patients with previously treated advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who, in their treating physician's opinion, have an unmet clinical need, are unlikely to obtain optimal benefit from currently approved and commercially available drugs, and who cannot enter a suitable clinical trial. conditions: Advanced Non-Small Cell Lung Cancer conditions: Metastatic Non Small Cell Lung Cancer studyType: EXPANDED_ACCESS name: Datopotamab deruxtecan sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Queen's Medical Center status: AVAILABLE city: Honolulu state: Hawaii zip: 96813 country: United States name: Principal Investigator role: CONTACT lat: 21.30694 lon: -157.85833 hasResults: False
nctId: NCT06279715 id: 3437 briefTitle: DFI and Aneuploidies overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-19 date: 2024-12-31 date: 2025-02-01 date: 2024-02-28 date: 2024-02-28 name: Clinique Ovo class: INDUSTRY briefSummary: IVF is the most commonly employed form of assisted reproductive technologies (ART) for the 10-15% of couples who face difficulties becoming pregnant. Many individuals elect to have their IVF-derived embryos analyzed using pregenetic implantation testing for aneuploidies (PGT-A). The use of PGT-A is particularly beneficial for patients at higher risk for aneuploidy, such as those of advanced maternal age and those faced with recurrent pregnancy loss or recurrent implantation failure.
Segmental aneuploidies are generated when a small piece of a chromosome is gained or lost during cell division, resulting in subchromosomal copy number (CN) changes. The frequency of segmental aneuploidies during the cleavage stage varies between studies, from as low as 3.9% to 15% and up to 70 % with no reported correlation with maternal age. This can be explained by the fact that, unlike whole chromosome aneuploidies, segmental aneuploidies most often involve paternally inherited chromosomes. conditions: Embryo Disorder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 800 type: ESTIMATED name: Preimplantation Genetic Testing for Aneuploidy measure: DFI association and aneuploidy sex: ALL minimumAge: 18 Years maximumAge: 43 Years stdAges: ADULT facility: Clinique ovo city: Montreal state: Quebec zip: H4P 2S4 country: Canada lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06279702 id: OCalisir briefTitle: Serious Game Simulation and Comics in School Students overallStatus: ACTIVE_NOT_RECRUITING date: 2023-07-19 date: 2025-07-19 date: 2025-07-19 date: 2024-02-28 date: 2024-02-28 name: TC Erciyes University class: OTHER briefSummary: The aim of the study is to determine the effect of first aid training for injuries given to secondary school students through serious game simulation and comic books on knowledge, skills and motivation.
METHOD: The research will be conducted as a randomized controlled experimental study with a pre-test-post-test design with children studying in the 5th and 6th grades of schools in the central district of Aksaray. One group will be given first aid training for injuries prepared with serious games, the other group will be given first aid training for injuries prepared with comic books. No intervention will be made to the control group. Serious game scenario software prepared based on the literature will be integrated into the computer. Appropriate statistics will be made after the research by applying the prepared data collection tools. With this research, the gap in the literature will be filled, children's first aid knowledge and skills in injuries will be increased, and school health nurses will be provided with up-to-date teaching material. conditions: First Aid studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: serious game and comics primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 54 type: ACTUAL name: SERIOUS GAME name: COMICS measure: Motivation Scale for Teaching Materials measure: Student Knowledge Level Evaluation Form for First Aid Application in Injuries measure: Student Skill Level Evaluation Form for First Aid Application in Injuries sex: ALL minimumAge: 9 Years maximumAge: 12 Years stdAges: CHILD facility: Özlem Çalışır city: Aksaray state: Center zip: 68200 country: Turkey lat: 38.37255 lon: 34.02537 hasResults: False
nctId: NCT06279689 id: CJTCDZ2301 briefTitle: Echography Study_Anthropometric Measurements overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2024-06 date: 2024-06 date: 2024-02-28 date: 2024-02-28 name: Crossject class: INDUSTRY briefSummary: This is a multi-center, exploratory, estimation study in both adult and pediatric populations. There is no investigational product injection during this study The exploratory objective of this study is to evaluate the anatomical characteristics of both anterolateral thighs in healthy adult and healthy pediatric populations (2 to 17 years old) by ultrasound scan before and while applying a force similar to the ZENEO® triggering force.
Only ultrasound procedures will be performed using an investigational ultrasound system. All subjects will be asked to undergo 1 on site visit (Study Visit) during which the eligibility assessment and the ultrasound scans will be performed. conditions: Healthy Subjects studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 90 type: ESTIMATED name: Ultrasound scans measure: STBD : Skin To Bone Distance measure: STMD: Skin To Muscle Distance measure: Thickness of skin layers (dermis, hypodermis) measure: Thickness of muscle layers measure: Circumferences measurements (thigh, upper arm, waist, hip) sex: ALL minimumAge: 2 Years maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279676 id: SaFeGreff briefTitle: Improvement of Women's Health After Allogeneic Stem Cell Transplantation acronym: SaFeGreff overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2028-07 date: 2028-12 date: 2024-02-28 date: 2024-02-28 name: Ciusss de L'Est de l'Île de Montréal class: OTHER name: Centre hospitalier de l'Université de Montréal (CHUM) briefSummary: The aim of this prospective research project is to better understand vulvovaginal cGVHD to improve care of allografted women. The expected outcomes include better knowledge of the incidence and manifestations of vulvovaginal cGVHD, risk factors, response to treatments and impact on sexual health of allotransplanted female patients. The knowledge acquired will allow transplant clinicians to make more precise recommendations for gynecological management of future allografted women. conditions: GVHD, Chronic studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Define the incidence and describe clinical presentation of vulvovaginal cGVHD after allogeneic stem cell transplants reflecting modern transplant practice. measure: Evaluate genital cGVHD treatment response measure: Evaluate the frequency of premature ovarian failure measure: Measure the incidence and prevalence of HPV infection measure: Evaluate the quality of life (QoL) of allografted women measure: Evaluate intimacy within relationships of allografted women measure: Evaluate sexual function of allografted women measure: Evaluate sexual distress of allografted women sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279663 id: NSTE-ACS Multivessel Trial briefTitle: Management Tactics for Patients High Risk With Acute Coronary Syndrome Without ST Segment Elevation and Multivessel Coronary Artery Disease acronym: NSTE-ACSMT overallStatus: RECRUITING date: 2024-02-29 date: 2028-12-31 date: 2029-12-31 date: 2024-02-28 date: 2024-03-13 name: Federal State Budgetary Institution National Medical Research Center named after academician E.N. Me class: OTHER_GOV name: Kemerovo Cardiology Center, Tarasov Roman Sergeevich name: Tomsk National Research Medical Center of the Russian Academy of Sciences, Ryabov Vyacheslav Valeryevich briefSummary: The study will include patients with acute coronary syndrome without ST segment elevation and multivessel CA lesion, who are subject to surgical treatment according to KG data (Syntax Score 23 - 32 points with significant damage to the anterior descending artery and/or trunk of the left coronary artery). The patient should be suitable for both CABG and PCI (confirmed by an X-ray surgeon and a cardiac surgeon). An X-ray surgeon and a cardiac surgeon, within the framework of planning the volume of revascularization, strives for the fullest feasible volume. Complete myocardial revascularization (that is, the desire for the absence of hemodynamically significant coronary arteries after revascularization, with a diameter of \> 2.5 mm, that is, residual coronary artery stenosis of no more than 60%). Thus, patients will be randomized into groups in a ratio of 1:1. Each group will need to include 230 patients (a total of 460). In the main group, revascularization will be performed by PCI, in the control group by CABG. conditions: Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 460 type: ESTIMATED name: Revascularization measure: Death from any cause measure: Combined endpoint (death from cardiovascular causes, MI, Stroke, repeated unplanned myocardial revascularization) measure: target LDL level measure: Myocardial infarction measure: Stroke measure: Repeated unplanned myocardial revascularization measure: Duration of the hospital period measure: Intra/perioperative complications measure: Significant hemorrhagic complications (grade 3 or more on the BARC scale) measure: Questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Anton status: RECRUITING city: Novosibirsk state: Novosibirsk Obl zip: 630055 country: Russian Federation name: Anton Obedinskiy, 1 role: CONTACT phone: +73833476099 phoneExt: 1 email: a_obedinskij@meshalkin.ru lat: 55.0415 lon: 82.9346 facility: Anton status: RECRUITING city: Novosibirsk state: Rechkunovskaya Str. zip: 630055 country: Russian Federation name: Anton Obedinskiy role: CONTACT phone: 89139322885 email: a_obedinskij@meshalkin.ru lat: 55.0415 lon: 82.9346 hasResults: False
nctId: NCT06279650 id: 2022-2741 briefTitle: Self-hypnosis Training for Chronic Pain Management overallStatus: RECRUITING date: 2024-02-01 date: 2024-06 date: 2024-12 date: 2024-02-28 date: 2024-02-28 name: Ciusss de L'Est de l'Île de Montréal class: OTHER briefSummary: Title: Self-hypnosis training in chronic pain management: A pilot study Our primary objective concerns the effect of hypnosis intervention on change in 24h pain between T0 (pre-intervention) and T4 (3-month follow-up). The secondary objectives concern the effects of the intervention on (i) change in 24h pain between T0 and T5 (6-month follow-up), (ii) changes from T0 in measures of the functional impact of pain, (iii) changes from T0 in anxiety-depression scores and (iv) changes from T0 in quality of life.
The study design is a Randomized efficacy pilot study. The study focuses on patients practicing self-hypnosis within HMR groups. The study population is pain clinic patients. The sample size is 60 pain clinic patients. Study duration: February 2024 - December 2024. Center responsible for the study: Centre de Recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR) - CEMTL, Montreal, Quebec, Canada.
Adverse events: none expected. conditions: Hypnosis, Chronic Pain Management studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Self-hypnosis name: Psycho-education and cognitive Bahavioral therapy (CBT) measure: Time 1 : Numerical Rating Scale (NRS) from 0 to 10 measure: Time 1 : Questionnaire Brief Pain Inventory (BPI) measure: Time 1 : Hospital anxiety and depression scale (HADS) measure: Time 1 : SF-36 (36-Item Short Form Survey) measure: Time 1 : Questionnaire socio-demographic and clinical measure: Time 2 : Numerical Rating Scale (NRS) from 0 to 10 measure: Time 2 : Questionnaire Brief Pain Inventory (BPI) measure: Time 2 : Hospital anxiety and depression scale (HADS) measure: Time 2 : SF-36 (36-Item Short Form Survey) measure: Time 3 : Numerical Rating Scale (NRS) from 0 to 10 measure: Time 3 : Questionnaire Brief Pain Inventory (BPI) measure: Time 3 : Hospital anxiety and depression scale (HADS) measure: Time 3 : SF-36 (36-Item Short Form Survey) measure: Time 4 : Numerical Rating Scale (NRS) from 0 to 10 measure: Time 4 : Questionnaire Brief Pain Inventory (BPI) measure: Time 4 : Hospital anxiety and depression scale (HADS) measure: Time 4 : SF-36 (36-Item Short Form Survey) measure: Time 5 : Numerical Rating Scale (NRS) from 0 to 10 measure: Time 5 : Questionnaire Brief Pain Inventory (BPI) measure: Time 5 : Hospital anxiety and depression scale (HADS) measure: Time 5 : SF-36 (36-Item Short Form Survey) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: 5415 Bd de l'Assomption status: RECRUITING city: Montréal state: Quebec zip: H1T 2M4 country: Canada name: David Ogez role: CONTACT email: david.ogez@umontreal.ca lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06279637 id: PRO00046457 briefTitle: Joint Patient and Caregiver Intervention for Older African Americans With Type 2 Diabetes overallStatus: NOT_YET_RECRUITING date: 2024-03-04 date: 2026-07 date: 2026-07 date: 2024-02-28 date: 2024-02-28 name: Medical College of Wisconsin class: OTHER briefSummary: This study will test the preliminary efficacy of a joint patient/informal caregiver telephone-delivered intervention that includes diabetes education; problem solving around social needs; and behavioral activation for older African Americans with poorly controlled type 2 diabetes by randomizing 100 patient/caregiver dyads to the Joint Home intervention (n=50) and usual care (n=50) arms.
Aim 3: To test the preliminary efficacy of home-based, joint patient and caregiver intervention (Joint Home-DM-BAT) on caregiver quality of life and caregiver burden. conditions: Type 2 Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Joint Home-DM-BAT Intervention name: Usual Care measure: Glycemic Control (Hemoglobin A1C [HbA1C]) sex: ALL minimumAge: 50 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False